However, given that approximately 20–25% of all NASH patients develop HCC in the absence of cirrhosis, it would be interesting to investigate more in-depth the role of adiponectin in non-cirrhotic NAFLD-associated HCC. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.